Novo's Saxenda bags FDA approval for weight management
This article was originally published in Scrip
With US FDA approval for Saxenda (liraglutide) Novo Nordisk could be a contender in the market for prescription weight loss drugs, which so far has yielded disappointing sales from oral obesity therapies approved in the US since 2012 starting with Belviq (lorcaserin) from Arena Pharmaceuticals.
You may also be interested in...
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.
Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.